Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › OUTSTAND-2 (HRS-7535-302, NCT06589765)

OUTSTAND-2 (HRS-7535-302, NCT06589765)

HRS-7535 · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
HRS-7535
Population
t2d
Official title
A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin
Sponsor
Shandong Suncadia Medicine Co., Ltd.
Phase
3
Registry status
completed · 2024-09 → 2026-05
Participants
810
Duration
32 weeks
Registry
NCT06589765

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
30 mg vs dapagliflozin 10 mg: HbA1c -1.28t2d china32810——−1.64.0—————press release
60 mg vs dapagliflozin 10 mg: HbA1c -1.28t2d china32810——−1.53.9—————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (4)
  • 30 mg · hba1c · press release
    Based on the efficacy estimand^3, the reductions in HbA1c from baseline for the HRS-7535 30 mg, 60 mg, and 90 mg groups and the dapagliflozin 10 mg group were 1.58%, 1.50%, 1.68%, and 1.28%, respectively.
  • 30 mg · ae_dc · abstract
    Adverse events leading to discontinuation occurred in 4.0%, 3.9% and 3.9% versus 1.0%
  • 60 mg · hba1c · press release
    Based on the efficacy estimand^3, the reductions in HbA1c from baseline for the HRS-7535 30 mg, 60 mg, and 90 mg groups and the dapagliflozin 10 mg group were 1.58%, 1.50%, 1.68%, and 1.28%, respectively.
  • 60 mg · ae_dc · abstract
    Adverse events leading to discontinuation occurred in 4.0%, 3.9% and 3.9% versus 1.0%

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: OUTSTAND-2 (HRS-7535-302, NCT06589765). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/outstand-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.